| General
Information |
|
1.1 |
|
What is phage display?
|
|
1.2 |
|
What are the advantages
of phage display screening over other methods of library screening? |
|
1.3 |
|
Can the Ph.D. libraries
be used interchangably with cDNA libraries? |
|
1.4 |
|
Are phage display cDNA
libraries available? |
|
1.5 |
|
What are the advantages
of M13 over other phage used for phage display applications?
|
|
1.6 |
|
What are the differences
between pIII and pVIII display? |
|
1.7 |
|
What is the size of
pIII with/without leader? |
|
1.8 |
|
Is the library cloning
vector available? |
|
1.9 |
|
Can the library be amplified
for additional panning experiments? |
|
1.10 |
|
Are anti-M13 antibodies
available? |
| |
| Applications |
|
2.1 |
|
For what applications
are these libraries ideally suited? |
|
2.2 |
|
Can the Ph.D. libraries
be used to find the natural ligands for a given protein? |
|
2.3 |
|
Can the libraries be
used to pan against intact cells? |
|
2.4 |
|
Can the Ph.D. libraries
be used for in vivo screening? |
|
2.5 |
|
For epitope mapping,
does the antibody need to be pure? |
|
2.6 |
|
Can the antibody be
polyclonal? |
|
2.7 |
|
Can I pan against DNA
to find sequence-specific DNA-binding peptides? |
| |
| Choice
of Library |
|
3.1 |
|
Which of the three libraries
should I buy? |
| |
| Troubleshooting |
|
4.1 |
|
Can a different bacterial
strain be used? |
|
4.2 |
|
The supplied bacterial
strain will not grow. |
|
4.3 |
|
No plaques are visible
when titering. |
|
4.4 |
|
All or most of the eluted
phage plaques are white (colorless) on Xgal/IPTG plates |
|
4.5 |
|
The amplified phage
titer is low. |
|
4.6 |
|
The phage DNA templates
do not yield readable sequence. |
|
4.7 |
|
The sequencing templates
do not run where they should on a gel. |
|
4.8 |
|
The sequence does not
have the cloning sites or insert as shown in Fig. 3. |
|
4.9 |
|
After 4 or more rounds
of panning all clones are wild-type phage (white plaques). |
|
4.10 |
|
The sequence is fine
back to the KpnI site, but then differs from Fig. 3, or the
KpnI site is missing altogether. |
|
4.11 |
|
The streptavidin control
experiment did not yield the HPQ consensus sequence. |
|
4.12 |
|
The ELISA indicates
that background binding to the plate is as high as binding to
the target. |
|
4.13 |
|
My selected sequences
bind BSA, and the protocol does not select against BSA-binders. |
|
4.14 |
|
Panning yielded a consensus
sequence, but no ELISA signal. |
|
4.15 |
|
A synthetic peptide
corresponding to an ELISA-positive sequence does not bind my
target. |
| |
| |
General
Information |
|
| 1.1 What is phage display? |
|
Phage display describes an in vitro selection
technique in which a peptide or protein is genetically fused
to a coat protein of a bacteriophage, resulting in display of
the fused protein on the exterior of the phage virion, while
the DNA encoding the fusion resides within the virion. This
physical linkage between the displayed protein and the DNA encoding
it allows screening of vast numbers of variants of the protein,
each linked to its corresponding DNA sequence, by a simple in
vitro selection procedure called "biopanning."
In its simplest form, biopanning is carried out by incubating
the pool of phage-displayed variants with a target of interest
that has been immobilized on a plate or bead, washing away unbound
phage, and eluting specifically bound phage by disrupting the
binding interactions between the phage and target. The eluted
phage is then amplified in vivo and the process repeated,
resulting in stepwise enrichment of the phage pool in favor
of the tightest binding sequences. After 3 rounds of selection/amplification,
individual clones are characterized by DNA sequencing.
top |
|
| 1.2 What are the advantages of phage
display screening over other methods of library screening? |
|
The main advantage of phage display over other
technologies is the ease with which one can screen large numbers
of clones. Standard screening of cDNA libraries, such as those
expressed in phage lambda, is limited by the number of plaques
or colonies which can be screened by hybridization, typically
on the order of 104. Synthetic random peptide libraries
are typically screened on grids of pins, where binding sequences
are identified by position, or on beads in suspension, where
bound sequences are identified by sequencing a tag affixed to
the selected bead. These technologies also limit the maximum
number of random peptides that can be screened to 103-104
different sequences. If synthetic peptides are screened in solution,
libraries can contain as many as 1015 different sequences,
but the requirement for sufficient material to sequence (~1
µg peptide) requires such low stringency during binding that
enrichments of only 100 to 1000-fold are possible, resulting
in selection of an enormous pool of peptides with highly variable
affinities. Using phage display, greater than 109
different displayed sequences can easily be screened, and since
the selected phage pool can be amplified by propagation in E.
coli, multiple rounds of selection can be carried out to
iteratively select for the tightest binding sequences.
top |
|
| 1.3 Can the Ph.D. libraries be used
interchangably with cDNA libraries? |
|
The choice of library depends on whether your
goal is to identify a sequence, natural or synthetic, which
binds to your target tightly, or solely to identify the natural
in vivo ligand for your target. Bear in mind that the
Ph.D. kits are based on fully randomized peptide libraries,
while cDNA expression libraries are limited to naturally occuring
proteins. As a result, the Ph.D. libraries are most suitable
for identifying novel ligands (e.g. receptor agonists) or mapping
the interactions between two known proteins (e.g. antibody epitope
mapping). Since the biopanning is carried out in vitro,
the selected sequence may bear little resemblance to any native
ligands for your target. For routine identification of the native
ligand for a protein, the yeast two-hybrid system, lambda gt11,
or other cDNA libraries may be more appropriate.
top |
|
| 1.4 Are phage display cDNA libraries
available? |
|
In general, M13 is not amenable to cDNA expression, due to the requirement for in-frame
expression between the leader sequence (required for secretion) and the N-terminus of coat protein pIII
or pVIII. The consequence of this requirement is that an insert must be in the correct reading frame at
both ends (p = 1/9) and contain no in-frame stop codons (p = [61/64] n/3, where n is the average insert
length in base pairs) in order for the corresponding protein sequence to be properly fused to the coat
protein. This results in a vanishingly small number of productive clones in M13 cDNA libraries. In contrast,
expression of cDNA inserts as C-terminal coat protein fusions is possible in the T7Select phage display
system available from Novagen (1-800-526-7319). This system utilizes the lytic bacteriophage T7 instead
of M13.
top |
|
| 1.5 What are the advantages of M13 over
other phage used for phage display applications? |
|
M13 and the closely related filamentous bacteriophages
fd and f1 are non-lytic, meaning that they do not lyse the host
during phage production. This greatly simplifies the intermediate
phage purification steps between rounds of panning, as a simple
PEG precipitation step is sufficient to separate the phage from
almost all contaminating cellular proteins. In contrast, other
phage that have been used for phage display (T7, T4, lambda)
are all lytic, necessitating additional time-consuming purification
steps between rounds to avoid panning amplified phage in the
presence of cellular proteins (including proteases which can
degrade your target during panning).
top |
|
| 1.6 What are the differences between
pIII and pVIII display? |
|
Filamentous phage display systems are generally
based on N-terminal fusions to the coat proteins pIII or pVIII.
pIII is present at 5 copies per virion, of which all 5 can be
fused to short peptides without interfering with phage infectivity.
The major coat protein pVIII is present at ~2700 copies per
virion, of which ~10% can be reliably fused to peptides or proteins.
As a result, peptides expressed as pIII fusions are present
at low valency (1-5 copies per virion), while pVIII fusions
are present at high valency (~200 copies per virion). The increased
avidity effect of high valency pVIII display permits selection
of very low affinity ligands, while low valency pIII display
limits selection to higher affinity ligands. All of the Ph.D.
libraries are pIII fusions (5 copies of the peptide per virion).
top |
|
| 1.7 What is the size of pIII with/without
leader? |
|
The molecular weight of the unprocessed coat protein
pIII (containing a leader sequence but no displayed peptide)
is 44651 daltons. Without the leader sequence, the molecular
weight of mature pIII is 42579. By SDS-PAGE, however, pIII usually
runs with an apparent molecular weight of 60-65 kDa, possibly
as a result of the unusual glycine-rich spacer regions between
the domains of the protein [van Wezenbeek et al. (1980)
Gene 11, 129-148]. The amino acid sequence of
the leader peptide is MKKLLFAIPLVVPFYSHS (note that the initiator
Met is encoded by a GTG codon).
top |
|
| 1.8 Is the library cloning vector available?
|
|
The vector used for constructing all three Ph.D.
libraries, M13KE, is available for sale. A derivative of M13mp19,
M13KE has restriction sites engineered at the 5´ end of
gene III permitting construction of custom peptide libraries
by insertion of a user-designed synthetic cassette. Because
M13KE is a phage, rather than a phagemid vector, all 5 copies
of pIII in the processed virions will carry the displayed peptide
sequence. Since displayed peptides longer than 20-30 residues
have a deleterious effect on phage infectivity, this vector
is suitable only for display of short peptide libraries, rather
than larger protein or cDNA libraries. The sequence of the vector
is available here.
The vector is available, for research use only, as part of
the Ph.D. Peptide
Library Cloning System, product #E8101S. In addition to
the vector, this product includes an extension primer for
second strand synthesis of the randomized library insert and
a detailed protocol for construction of random peptide libraries
in M13KE.
top
|
|
| 1.9 Can the library be amplified for
additional panning experiments? |
|
We strongly recommend against amplification of
the supplied libraries, as sequence biases in vivo will
likely result in certain sequences being underrepresented in
the resulting library, or absent altogether. Displayed peptides
in the Ph.D. libraries are expressed as fusions to the coat
protein pIII, which modulates infectivity by binding to the
F-pilus of the recipient cell. As a result, there is a biological
selection against certain displayed sequences during in vivo
amplification, particularly sequences with multiple positive
charges (which inhibit secretion) and unpaired cysteines. The
supplied libraries have each been amplified only once following
ligation, and all characterization (representative sequencing,
panning etc.) carried out on this amplified selling stock. We
cannot guarantee that the amino acid distribution data we report
for each library as supplied will hold upon reamplification.
top |
|
| 1.10 Are anti-M13 antibodies available?
|
|
We recommend the following anti-M13 antibodies,
both available from GE Healthcare (800-526-3593). Both antibodies
are polyclonal and recognize primarily pVIII.
| Anti-M13 antibody |
#27-9420-01 |
| Anti-M13 antibody, HRP conjugated |
#27-9421-01 |
| top |
|
|
| |
Applications |
|
| 2.1 For what applications are these
libraries ideally suited? |
|
Over the last ten years, the Ph.D. libraries from New England Biolabs have become the
dominant tools in this field, with hundreds of publications describing applications including epitope
mapping/vaccine development (Youn, et al (2004) FEMS Immunol. Med. Microbial. 41,
51-57; Eshaghi et al. (2006) Mol. Immunol.43, 268-278), mapping protein-protein
contacts (Carter et al. (2006) J. Mol. Biol. 357, 236-251 ) and identification
of peptide mimics of non-peptide ligands (Hou and Gu (2003) J. Immunol.170,
4373-9). Bioactive peptides, which can be used as cell-targeting or gene delivery agents, have been identified
either by panning against purified receptors (De et al. (2006) Biochem. Biophys. Res. Commun. 342,
956-62) or against intact cells or tissue samples, both in vitro and in vivo (Kragler (2000) EMBO
J.19, 2856-68). It is apparent that applications of the Ph.D. kits have been limited
only by the imagination of the scientific community. Please see our applications page for additional
references: http://www.neb.com/nebecomm/tech_reference/drug_discovery/phd_application_references.asp
top
|
|
| 2.2 Can the Ph.D. libraries be used
to find the natural ligands for a given protein? |
|
Since the Ph.D. libraries consist of fully randomized
peptides displayed on phage, a binding peptide identified in
a particular panning experiment will not necessarily correspond
to a "natural" ligand for the target. The biopanning
procedure iteratively selects for those peptides which best
bind the target under the panning conditions in vitro,
without regard to the biological role of the target in vivo.
For certain targets, such as antibodies with linear epitopes,
the selected sequence will in all likelihood correspond to that
region of your antigen recognized by the antibody. For targets
which bind to large surfaces of a protein, or discontinuous
regions of the primary sequence, the selected sequences are
less likely to resemble the "natural" ligand. As a
result, caution should be taken if you are planning on using
the DNA corresponding to the selected sequences as probes when
trying to clone any natural ligand proteins. In contrast, cDNA
expression libraries are by nature limited to natural proteins,
and as a result are much more likely to yield the native ligand
for your protein. If your goal is to identify a sequence, natural
or synthetic, which binds to your target tightly, then you should
consider biopanning with the Ph.D. libraries. If you are only
interested in identifying the natural ligand for your target,
however, you should consider screening an appropriate cDNA library
expressed in lambda gt11 or two-hydrid system.
top |
|
| 2.3 Can the libraries be used to pan
against intact cells? |
|
Yes. There are numerous reports in the literature
describing the use of libraries very similar to the Ph.D. libraries
for identification of novel ligands for cell-surface receptors
by panning against intact cells. Keep in mind, however, that
a given cell type will have hundreds or thousands of different
receptors, each capable in theory of pulling a ligand out of
the library. As a result, simple panning against intact cells
will likely yield a complex mixture of peptides with no clear
consensus. To target the library to the receptor of interest,
it is necessary either to elute bound phage with a known ligand
for that particular receptor, or to carry out subtractive panning
with cells that do not express the receptor. This is accomplished
by having two cell lines, identical except for the presence
or absence of the receptor of interest. The library is incubated
with the cells without the receptor, and then the supernatant
is added to cells expressing the receptor. Phage that bind to
the second cell line are then amplified and taken on to the
next round. Because of nonspecific binding of peptides to cell
surfaces, however, we recommend carrying out the subtractive
panning step beginning with the second round. For more details
consult the following references:
- Doorbar, J. and Winter, G. (1994). Isolation of a peptide
antagonist to the thrombin receptor using phage display.
J. Mol. Biol. 244, 361-369.
- Goodson, R.J. et al. (1994). High-affinity urokinase
receptor antagonists identified with bacteriophage peptide
display. Proc. Natl. Aad. Sci. USA 91, 7129-7133.
- Barry, M.A., Dower, W.J., and Johnston, S.A. (1996). Toward
cell-targeting gene therapy vectors: Selection of cell-binding
peptides from random peptide-presenting phage libraries.
Nature Medicine 2, 299-305.
- Szardenings, M. et al. (1997) Phage display selection
on whole cells yields a peptide specific for melanocortin
receptor 1. J. Biol. Chem. 272, 27943-27948.
top
|
|
| 2.4 Can the Ph.D. libraries be used
for in vivo screening? |
|
An exciting recent development is the use of phage display to select organ-specific peptides in
vivo. Peptides selected in this manner have been successfully used to specifically deliver drugs
to tumor cells.
- Pasqualini, R. and Ruoslahti, E. (1996). Organ targeting
in vivo using phage display peptide libraries. Nature
380, 364-366.
- Arap, W., Pasqualini. R. and Ruoslahti, E. (1998) Cancer
treatment by targeted drug delivery to tumor vasculature
in a mouse model. Science 279, 377-380.
- Chen et al. (2006) Transdermal protein delivery by coadministered peptide identified via phage
display. Nat. Biotech.24, 455-460.
top
|
|
| 2.5 For epitope mapping, does the antibody
need to be pure? |
|
We recommend Protein A purification of antibodies
for epitope mapping. However, the major component of crude serum
or ascites fluid is serum albumin, which is used in the blocking
step anyway. Following the direct coating method in the Manual,
you can coat with serum or ascites fluid (diluted 1:10 in TBS)
and omit the blocking step. If using the Protein A/Protein G
bead capture protocol, use 1 µL of serum or ascites fluid in
place of the antibody in Step 5. In this case it is necessary
to carry out the blocking step (Step 4) as described. However,
given the variable level of antibody in serum or ascites, we
cannot guarantee the crude antibody preps will work.
top |
|
| 2.6 Can the antibody be polyclonal?
|
|
Maybe. A polyclonal antibody raised against a
large antigen will likely contain numerous epitope specificities
corresponding to different regions of the antigen and, if the
antibody has not been affinity purified, other antigen specificities
as well. When panning against such a heterogeneous population
of antibodies, it is unlikely that a well-defined consensus
epitope sequence will emerge. Rather, numerous sequences corresponding
to the individual specificities will be selected, which will
be difficult to discern against the background of non-binding
sequences. For smaller antigens, the number of selected epitope
sequences will likely be more manageable, particularly if the
antibody is affinity purified. Experiments at New England Biolabs
have demonstrated that polyclonal antibodies raised against
peptide antigens yield clear consensus epitope sequences.
top |
|
| 2.7 Can I pan against DNA to find sequence-specific
DNA-binding peptides? |
|
Probably not. In general, the sequence specificity
of DNA binding proteins results from a series of precisely oriented
hydrogen bonds between side chains of the protein and the nucleotide
bases. This requires that the side chains responsible for sequence
recognition be precisely fixed in position by the tertiary structure
of the protein, which is not possible with short unstructured
peptides. Additionally, the sequence specificity represents
only a fraction of the overall binding energy, the bulk of which
comes from nonspecific interactions with the phosphodiester
backbone of the DNA. As a result, attempts to select for sequence-specific
DNA-binding peptides by phage display have generally resulted
in peptides with multiple positively-charged residues that bind
to the phosphodiester backbone of the DNA, but not sequence-specifically.
Phage display has proven extremely successful, however, for
selection of zinc finger domains with altered sequence specificity.
Residues known to be important for sequence discrimination are
randomized, and the resulting pool of specificity variants is
biopanned against specific DNA sequences. See Choo and Klug
(1995) Curr. Opin. Biotech. 6, 431-436.
top |
| |
Choice
of Library |
|
| 3.1 Which of the three libraries should
I buy? |
|
The Ph.D.-7 library consists of randomized linear
7-mer peptides, fused to the coat protein pIII of M13 via a
flexible linker, Gly-Gly-Gly-Ser. The first residue of the mature
fusion protein is the first randomized position. The library
contains 2.8 x 109 independent clones, sufficient
to encode most if not all of the 207 = 1.28 x 109
possible 7-residue sequences. The Ph.D.-7 library is most useful
for targets requiring binding elements concentrated in a short
stretch of amino acids. It is the best characterized library
we sell, and in the absence of other considerations we recommend
trying this library first.
The Ph.D.-12 library consists of randomized linear 12-mer
peptides, also fused to pIII via the flexible linker Gly-Gly-Gly-Ser.
The library contains 1.9 x 109 independent clones,
or only a small fraction (less than 1 millionth) of the 2012
= 4.1 x 1015 possible 12-mer sequences. The Ph.D.-12
library can be thought of as having the equivalent diversity
of a 7-mer library, but spread out over 12 residues. This
is useful for targets requiring 7 or fewer defined residues
for binding, but which cannot be contained within the 7-residue
"window" of the Ph.D.-7 library. For example, the
motif ASDXXXTXPY has only six defined positions, but cannot
be present in the Ph.D.-7 library. Additionally, 12-mers are
long enough to fold into short structural elements, which
may be useful when panning against targets that require structured
ligands. A caveat is that the increased length of the randomized
segment may allow your target to select sequences with multiple
weak binding contacts, instead of a few strong contacts.
The Ph.D.-C7C library consists of randomized 7-mer peptides,
each flanked by a pair of cysteine residues. In the absence
of reducing agents, these cysteines spontaneously form a disulfide
bond, resulting in each peptide in the library being constrained
in a disulfide loop. The library contains 3.7 x 109
independent clones . Like the other libraries, the library
is fused to pIII via the Gly-Gly-Gly-Ser spacer. The Ph.D.-C7C
library is useful for targets whose native ligands are in
the context of a surface loop, such as antibodies with structural
epitopes. Additionally, imposing structural constraint on
the unbound ligand results in a less unfavorable binding entropy,
improving the overall free energy of binding compared to unstructured
ligands. A major disadvantage of the Ph.D. -C7C library is
that the disulfide constraint may "freeze out" a
conformation required for target binding. The bottom line
is that it is impossible to predict in advance which library
is suitable for a given target. As a result, we recommend
that the Ph.D.-7 library be tried first, regardless of target.
Alternatively, all three libraries can be tried simultaneously,
as it is very simple to carry out panning experiments in parallel
using multiwell plates.
top
|
| |
Troubleshooting |
|
| 4.1 Can a different bacterial strain
be used? |
|
In theory other F+ strains containing
the supE suppressor mutation (such as XL1-Blue and DH5aF')
should work with our phage display system. However, we have
not tested these strains with our libraries and do not know
whether there will be any subtle effects on the expression or
transport of certain peptides out of the cell. Since the Ph.D.
libraries were made in ER2738 we know that all the peptides
in the libraries can be successfully expressed in this strain.
Therefore, we recommend this strain over any other one.
top |
|
| 4.2 The supplied bacterial strain will
not grow. |
|
Glycerol stocks of ER2738 should be stored at -80°C and ideally, upon receipt
of the kit, multiple fresh glyercol cultures should made. These, never thawed, will last for many years
in storage. Glycerol stocks have a shorter lifetime at -20°C. If colonies do not appear after
streaking a plate, we recommend spreading 20-50 µL of ER2738 stock onto an LB/Tet plate. Alternatively,
liquid culture can be inoculated and then a plate should be made by streaking turbid culture. If liquid
cultures do not grow in LB/Tet, a fresh plate of ER2738 will usually solve the problem. Additional glycerol
cultures of ER2738 (#E4104S) can be ordered for the cost of shipping.
top
|
|
| 4.3 No plaques are visible when titering.
|
|
Unlike lambda, M13 is a non-lytic phage and does
not produce clear plaques. M13 plaques are areas of diminished
cell growth, not lysis, and consequently can be difficult to
see. Try holding the plate up to a light. Also, since the vector
used to prepare the library carries the lacZa gene, plaques
will be blue, and easier to see, when using an a-complementing
strain such as the supplied strain ER2738 and plating on Xgal/IPTG
plates. Also, be sure the dilution range is appropriate for
the phage you are titering. For amplified phage, plate 10 µL
of 1:109 - 1:1011 dilutions; for unamplified
panning eluates, try 1:10 - 1:104 dilutions for early
rounds, 1:104-1:107 for later rounds.
If the phage is not sufficiently dilute, the plaques will be
confluent on the plate and it will look like there are no plaques
at all (or a bluish tinge when using Xgal plates). Occasionally
after PEG precipitation, the phage will clump and not dilute
properly. As a result, you might have a plate containing too
many plaques merged together. Make sure togive the phage ample
time to resuspend after precipitation (>1 hour) and vortex
each dilution tube very well (~10 seconds).
top |
|
- 4.4 All or most of the eluted phage plaques are white (colorless)
on Xgal/IPTG plates
|
|
If all of your plaques are white (colorless),
it is possible that the Xgal/IPTG plates were incorrectly prepared.
Test your plates by titering the naive unpanned library, using
109 and 1010 dilutions. If both the unpanned
library and your selected phage produce white plaques, then
the plates are defective and should be carefully re-prepared.
Also, the bacterial strain used for plating must be capable
of a-complementation (lacZDM15 or equivalent),
such as the supplied strain ER2738, in order for blue/white
screening to work. The most likely explanation for white plaques
is that the pool of phage became contaminated with an environmental
M13-like phage during panning and amplification. Display of
foreign peptides as N-terminal fusions to the infectivity protein
pIII, as in the Ph.D. libraries, slightly attenuates infectivity
of the library phage relative to wild-type M13. As a result,
there is an in vivo selection for the contaminating phage
during the amplification steps between rounds of panning. In
the absence of a correspondingly strong in vitro binding
selection during panning, even vanishingly small levels of contamination
can result in a majority of the phage pool being wild-type phage
after 3 (or especially 4) rounds of panning. The Ph.D.-C7C library
is particularly susceptible to contamination, since phage infectivity
is further attenuated by displayed cysteine-containing peptides.
Contamination is an extremely common problem with any phage
display system, but fortunately there are a few things you can
do to minimize this problem:
a) Use Xgal/IPTG plates for all titering steps, and if
white plaques are evident, pick only blue plaques for sequencing.
b) Use aerosol-resistant pipet tips and cotton-plugged
pipets for all protocols described in the Manual.
c) If contamination problems persist, all of the solutions
used for panning should be autoclaved, with the exception
of BSA-containing solutions which should be filter sterilized.
Solutions used for phage display should not be used for
anything else. Pipettors should be disassembled, the barrel
autoclaved, and the internal plunger machinery soaked overnight
in a detergent solution such as Count-Off.
d) Since wild-type phage are preferentially amplified during
the amplification steps, pick plaques for sequencing directly
after the 3rd round elution step. Do not amplify the 3rd
round eluate and carry out a 4th round unless the third
round sequences show no clear consensus.
e) If all or most of the plaques are white (colorless)
after 3 rounds of panning, it is possible that the library
simply does not contain any clones that bind tightly to
the target. The ideal ligand sequence may not be statistically
represented in the library, or the target simply is not
capable of binding to a short peptide sequence. In the case
of the C7C library, where all the peptides are constrained
in a disulfide loop, a ligand sequence where the imposed
constraint allows a productive binding conformation will
bind more tightly than the same linear sequence due to improved
binding entropy. However, if the imposed constraint does
not allow a productive binding conformation, than that sequence
will likely not bind to the target at all. In this case
either of our linear libraries may yield better results.
|
|
top |
|
| 4.5 The amplified phage titer is low.
|
|
In order for M13 phage to be efficiently amplified,
it is critical that cultures be well aerated, and that cultures
be infected early in their growth phase. We recommend amplification
in 20 mL cultures in 250 mL Erlenmeyer flasks, in a shaker set
to 250 rpm. Amplification in smaller vessels, such as 50 mL
conical tubes, will result in much lower yields of amplified
phage. M13 phage should either be added to an early-log culture,
A600 <0.01, or to a 1:100 dilution of an overnight
culture. Yield of amplified phage is maximal after 4.5-5 hours
at 37°; longer incubation may result in deletions and is
not recommended. If carrying out nonspecific elution with pH
2.2 glycine buffer, the eluted phage must be neutralized as
described in the Manual prior to amplification.
top |
|
| 4.6 The phage DNA templates do not yield
readable sequence. |
|
The sequencing template purification protocol in the Manual should provide single- stranded
template of sufficient purity for dideoxy sequencing with Sequenase™ (GE Healthcare), or automated
cycle sequencing with dye-labeled terminators (ABI). The procedure should be followed exactly as described
in the Manual: prolonged ethanol precipitation, precipitation at -20°C or centrifugation longer than
10 minutes will result in co-precipitation of salt and phage proteins, which will inhibit sequencing. Additionally,
it is crucial that the phage pellet is thoroughly suspended in the iodide buffer prior to adding ethanol.
If problems persist, or if another sequencing method is used, a phenol:chloroform extraction step can be
added: Following suspension in Iodide Buffer, add 2 volumes of TE, extract once with phenol:chloroform
(1:1) and once with chloroform, and ethanol precipitate. Another option is to isolate double-stranded template
from the cell pellet by standard plasmid purification procedures. 5 µL of suspended template (approximately
0.5 µg) should be sufficient for sequencing; quantitation should be confirmed by agarose gel electrophoresis
using 0.5 µg single stranded M13 DNA (NEB #N4040S) as a standard.
top |
|
| 4.7 The sequencing templates do not
run where they should on a gel. |
|
The sequencing templates prepared by the method in the Manual are single-stranded (approx.
7250 nucleotides), and as a result will not line up with double-stranded markers of the same length.
The apparent size will vary depending on the applied voltage, ethidium and agarose concentration in the
gel, and whether TBE or TAE is used as running buffer. We strongly recommend using single-stranded M13
DNA (e.g. single-stranded M13mp18, NEB #N4040S, $30 ( USA) for 10
µg) as a marker.
top
|
|
| 4.8 The sequence does not have the cloning
sites or insert as shown in Fig. 3. |
|
If the sequence matches the sequence in Figure
3 from the primer back to the 3´ G of the EagI
site, but then deviates upstream from this position, you may
have sequenced a wild-type M13 contaminant (see white plaques,
above):
EagI
Fig. 3 sequence: ...GGTGGAGGTTCGGCCGAAACTGTTGAA...
||||||||||||
wt M13 sequence: ...TATTCTCACTCCGCTGAAACTGTTGAA...
Since the library phage are derived from the common cloning
vector M13mp19, which carries the lacZa gene, phage
plaques appear blue when plated on media containing Xgal and
IPTG, providing an a-complementing strain such as ER2738 is
used for plating. Environmental M13-like phage will typically
yield white plaques when plated on the same media. These plaques
are also slightly larger and "fuzzier" than the
library phage plaques. We therefore recommend plating on LB/Xgal/IPTG
plates for all titering steps and, if white plaques are evident,
picking ONLY blue plaques for sequencing.
top
|
|
- 4.9 After 4 or more rounds of panning all clones are wild-type
phage (white plaques).
|
|
In a typical round of biopanning, 2 x 1011
input phage are reacted with the target, and between 103
and 107 total phage are eluted off following washing.
This corresponds to an enrichment of 104 to 108-fold
per round. Since the library contains approx. 2 x 109
different clones, the eluted pool of phage should in theory
be fully enriched in favor of binding sequences after only 2
or 3 rounds. Once this point is reached, further rounds of amplification
and panning will result only in selection of phage that have
a growth advantage over the library phage. For example, vanishingly
small levels of contaminating environmental wild-type phage
(less than one part per billion) will completely overtake the
pool if too many rounds of amplification are carried out, regardless
of the strength of the in vitro selection.
top |
|
| 4.10 The sequence is fine back to the
KpnI site, but then differs from Fig. 3, or the KpnI site is missing altogether. |
|
If the sequence matches the sequence in Figure
3 starting from the primer back to the KpnI site, but
then deviates upstream from the KpnI site (or the KpnI site is missing), the clone likely
contains multiple inserts. All of the Ph.D. libraries were constructed by directional cloning
of a synthetic randomized duplex into KpnI and EagI sites that had previously been engineered
into the M13 genome. A small percentage (<1%) of clones in each library picked
up more than one insert during ligation. Typically such clones
contain 2-5 randomized inserts, with one or more inverted relative
to the others. Preferential selection and amplification of these
clones may occur when panning against targets which prefer longer
ligands; consequently, selection of clones with multiple inserts
is more likely to occur when using the Ph.D.-7 library. To properly
characterize these clones, it is necessary to read the sequence
back to the occurrence of a Kpn I site preceded by the
upstream vector sequence TTAGT, as shown in Figure 3. Starting
from this KpnI site, the translated sequence Val-Pro-Phe-Tyr-Ser-His-Ser
is the C-terminal end of the pIII leader sequence. Everything
downstream from this sequence is displayed on the phage, and
must be considered when identifying consensus binding elements.
In experiments carried out at NEB, however, we have failed to
identify meaningful consensus binding motifs from multiple insert
clones, and typically ignore these clones when interpreting
data. If all or most of your selected clones contain multiple
inserts, we recommend repeating your panning with the Ph.D.-12
library.
top |
|
| 4.11 The streptavidin control experiment
did not yield the HPQ consensus sequence. |
|
If you used low pH glycine rather than biotin
to elute your phage, you will likely not get an HPQ consensus
sequence. Due to the relatively low affinity of the peptide-streptavidin
interaction, nonspecific elution is incapable of selectively
enriching for HPQ-containing peptides. HPQ-containing peptides
can be competitively eluted using the natural ligand biotin.
If you used biotin to elute and still did not get a consensus
sequence, the most likely explanation is that you did not carry
out sufficiently rigorous washes. When you wash, pour the wash
buffer in the plate from a bottle (don't gently pipet it in)
and swirl it for about 10 seconds each time. The number of phage
that you elute after the first round of biopanning should be
in the range of 103 - 107 (closer to 103
for an ELISA well and closer to 107 for larger wells).
If you are eluting more phage, you are not washing well enough
and as a result, not getting sufficient enrichment. It also
may help to add 0.1 µg/ml streptavidin to the blocking buffer
to complex any contaminating biotin in your BSA, which could
otherwise complex the streptavidin on the plate during the blocking
step.
top |
|
| 4.12 The ELISA indicates that background
binding to the plate is as high as binding to the target.
|
|
If panning against a polystyrene plate coated with the target (direct coating method), it
is possible to inadvertently select peptides that specifically bind the polystyrene surface (see Adey et
al. (1995) Gene156, 27-31; Menendez. and Scott (2005) Anal. Biochem.336,
145-157.). These peptides will yield identical ELISA signals in the presence and absence of target, since
the ELISA plate is also made of polystyrene. Such "plastic binders" are typically rich in aromatic
residues (Phe, Tyr, Trp, His), which often alternate (the sequence FHWTWYW is a plastic binder discovered
and characterized at NEB). Selection of plastic binders often occurs in the absence of a strong target
preference for peptide sequences present in the library: other libraries may yield the desired target-specific
sequences. Selection of polystyrene-specific peptides can be avoided by using the bead capture protocol
described in the Manual. The phage is reacted with the target in solution, and the phage-target complexes
are then captured onto beads that specifically bind the target (protein A-agarose for antibody targets,
glutathione-agarose for GST fusions, etc.). Unbound phage is removed by extensively washing the beads in
a microfuge tube. Unlike polystyrene, neither the beads (typically crosslinked agarose) nor the microfuge
tube (polypropylene) are likely to select specific peptide sequences from the library, although the species
conjugated to the beads (protein A, glutathione, etc.) might. To avoid selection of bead-specific ligands,
we suggest either alternating rounds between different beads specific for the target (e.g. protein A beads
for rounds 1 and 3, protein G beads for round 2 for antibody targets), or adding a subtractive panning
step, beginning with round 2, in which the phage pool is first reacted with the beads alone (no target),
the beads discarded, and the supernatant from this step reacted with the target.
top |
|
| 4.13 My selected sequences bind BSA,
and the protocol does not select against BSA-binders. |
|
Most likely the "BSA-binding" sequences are actually binding to the polystyrene
surface of the plate rather than the BSA (see previous answer). BSA is a soluble, monomeric globular protein
without a defined ligand binding site. This means that the entire surface of the protein has evolved to
specifically bind water (the definition of "soluble"), so it is unlikely that a peptide could
bind specifically to the surface of the BSA in the presence of 55 M water during panning. Contrast this
to the case where the target protein HAS a defined ligand binding site, such as an antibody. In this case,
the surface of the protein has evolved to bind water, but the water in the ligand binding site is bound
LESS tightly and can be displaced by the ligand. So when binding a phage library to an antibody, specific
ligands in the library are able to displace the water in the ligand binding site of the antibody, but do
not bind elsewhere on the surface of the antibody. This is why nonspecific elution (0.2 M glycine, pH 2.2)
generally yields peptides that are specific for the ligand binding site of the antibody, even though the
antibody has a vast surface area containing many more potential binding sites. The bottom line is that
for small peptide ligands, there is generally not enough potential binding energy to displace water from
the non-ligand-binding surface of proteins. The absence of a defined ligand binding site is precisely why
BSA is generally used for blocking in phage display applications. In contrast, the phenomenon of plastic
binding peptides is well documented (see above).
top |
|
| 4.14 Panning yielded a consensus sequence,
but no ELISA signal. |
|
When characterizing phage clones by the ELISA protocol in the Manual, it is difficult
to add more than 1012 virions per 100 µL well. This corresponds to a phage concentration of only
16 nM. At this concentration, an unambiguously positive ELISA signal can only be observed if the binding
affinity is in the micromolar range or better. The iterative nature of phage selection permits identification
of ligands with a broad range of affinities, from sub-nanomolar to 1 millimolar, so lower affinity ligands
will not show a positive ELISA signal. In this case it is necessary to increase the concentration of
the selected ligand, either by synthesing a peptide corresponding to the selected sequence (be sure to
include the spacer sequence GGGS at the C-terminus, and amidate the C-terminal carboxylate if possible),
or by expressing the selected sequence as an N-terminal fusion to a smaller protein (e.g. an MBP fusion
constructed with pMal-pIII, NEB #N8101S). Alternatively, a sandwich ELISA can be carried out in which
the selected phage is immobilized and an excess of target applied in the liquid phase. This procedure
requires an antibody against the target protein, or some other means of detecting bound target protein.
Coat the wells overnight with anti-M13 antibody (no HRP), wash, and add serial dilutions of each phage
clone (one clone per row). After 1 hour, wash away unbound phage and add an excess of target protein
(0.1 - 1 µM) in TBST. Incubate 1-2 hours at RT°, wash away unbound target, and detect bound
target with an enzyme-linked antibody.
top
|
|
| 4.15 A synthetic peptide corresponding
to an ELISA-positive sequence does not bind my target. |
|
If a selected sequence binds the target in the
context of intact phage, but not as a synthetic peptide, it
is possible that the selected sequence requires additional elements
from the adjacent spacer sequence for binding. Bear in mind
that, while the N-terminus of the selected peptide sequence
was free during panning, the C-terminus was fused to the phage.
Furthermore, the C-terminal residue of the selected sequence
did NOT have a free negatively-charged carboxylate during panning,
so a simple synthetic peptide with a free carboxy terminus will
introduce a negatively charged group at a position occupied
by a neutral peptide bond during panning, which may completely
abolish binding. When designing synthetic peptides corresponding
to selected sequences, we recommend adding the spacer sequence
Gly-Gly-Gly-Ser to the C-terminus, and if possible, amidating
the C- terminal carboxylate to block the negative charge. For
chemical conjugation of the peptide to a reporter enzyme, the
C-terminal serine can be replaced with cysteine (if there are
no other cysteines present in the sequence). The resulting peptide
thiol can be easily coupled to maleimide-activated HRP or alkaline
phosphatase (both available from Pierce).
top |
|
|
 |
| Last Updated: 1/29/2007 |
|
|